Acute, symptomatic catheter‐associated DVT with mobile, intra‐cardiac thrombus in an infant with severe haemophilia A

1 Franchini M, Favaloro EJ, Lippi G. Mild hemophilia A. J Thromb Haemost 2010; 8: 421–32. 2 Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998; 4: 558–63. 3 Mauser-Bunschoten EP, Den Uijl IE, Schutgens RE, Roosendaal G, Fischer K. Risk of inhibitor development in mild haemophilia A increases with age. Haemophilia 2012; 18: 263–7. 4 Hay CR, Ludlam CA, Colvin BT et al. Factor VIII inhibitors in mild and moderateseverity haemophilia A. Thromb Haemost 1998; 79: 762–6. 5 Eckhardt CL, Menke LA, Van Ommen CH et al. Intensive peri-operative use of factor VIII and the Arg593 > Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J Thromb Haemost 2009; 7: 930–7. 6 Cid AR, Casana P, Cabrera N, Haya S, Cortina V, Azmar JA. Inhibitor development in one patient and laboratory discrepancies in several families with both mild haemophilia and Arg531Cys mutation. Haemophilia 2007; 13: 206–8. 7 Shima M. Characterization of factor VIII inhibitors. Int J Hematol 2006; 83: 109– 18. 8 Eckhardt CL, Mauser-Bunschoten EP, Peters M, Leebeek FW, van der Meer FJ, Fijnvandraat K. Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: a prospective national study in the Netherlands. Br J Haematol 2012; 157: 747–52. 9 Shibata M, Shima M, Morichika S et al. An alloantibody recognizing the FVIII A1 domain in a patient with CRM reduced haemophilia A due to deletion of a large portion of the A1 domain DNA sequence. Thromb Haemost 2000; 84: 442–8. 10 d’Oiron R, Pipe SW, Jacquemin M. Mild/ moderate haemophilia A: new insights into molecular mechanisms and inhibitor development. Haemophilia 2008; 14: 138–46.